ABSTRACT
In a multicentric general-practice-study 2504 hyperlipoproteinemic patients were treated with etofibrate retard for 4 weeks. The drug was administered once daily in the evening. A highly significant decrease of the mean values of cholesterol around 18.4% and 27.6% resp., and of the mean triglycerides between 31.3% and 16.5% resp. were observed. The atherogenic index was reduced by 28%. The simultaneous, highly significant reduction of blood glucose and of uric acid levels as well as of blood pressure showed the comprising effects of etofibrate retard against the atherosclerosis and its risk factors. The excellent tolerance of the drug was stated by more than 99% of the patients treated.
Subject(s)
Arteriosclerosis/drug therapy , Clofibrate/analogs & derivatives , Clofibric Acid/analogs & derivatives , Hypolipidemic Agents/therapeutic use , Arteriosclerosis/blood , Blood Glucose/metabolism , Cholesterol/blood , Clofibric Acid/therapeutic use , Delayed-Action Preparations , Female , Hemodynamics/drug effects , Humans , Lipoproteins, HDL/blood , Lipoproteins, LDL/blood , Male , Middle Aged , Triglycerides/blood , Uric Acid/bloodABSTRACT
Nicotinic acid is used widely in the treatment of hyperlipoproteinemias and reduces both the cholesterol and the triglyceride concentrations in the plasma. However, very high doses are needed to achieve these therapeutic effects, which is why side effects are common and are particularly known to hinder the compliance of patients. Nicotinic acid derivatives have been developed to overcome this problem. As a result of chemical and galenic retardation, these derivatives lessen the side effects and the necessary doses are considerably reduced in comparison with pure nicotinic acid. However, most of these derivatives are not pure prodrugs, and exert their own synergistic pharmacokinetic and pharmacodynamic effects. In general, when nicotinic acid and its derivatives are used in therapy a desirable modification of the composition of the plasma lipids in the sense of an antiatherosclerotic activity can be expected (reductions of VLDL and LDL and an increase of HDL). Good possibilities for using nicotinic acid in the prevention and remission of atherosclerotic processes arise in connection with the activation of fibrinolysis and the reduction of the tendency toward platelet aggregation. In the light of recent studies on the mechanisms of action of nicotinic acid, an influence on the prostaglandin system has been found, as a result of which an interconnection between its various effects and side effects appears to be possible.
